10 results about "Transmissible gastroenteritis virus" patented technology

The invention belongs to the technical field of virus immunodetection, and relates to detection of swine transmissible gastroenteritis virus, in particular to a Mab 12H6 antibody, a colloidal gold test strip and application. According to the invention, TGEV N protein is used as an antigen of a detection line, Mab 12H6 is used as a detection antibody combined with colloidal gold, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on an N protein TGEV colloidal gold competition method is established. The established TGEV colloidal gold test strip has the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of TGEV in a porcine diarrhea sample clinically.

This application discloses the application of creatine in the preparation of drugs or feed additives for the treatment or prevention of pathogenic diarrhea in pigs. The drugs are creatine or creatine as an active ingredient with added excipients to form oral liquids, granules, tablets, or powders. The dosage is 30–300 mg / kg of pig body weight; or it can be directly added to feed at a creatine content of 0.05%–0.5% of the total weight of the pig feed. The drugs or feed additives provided in this application are highly safe, have no toxic side effects, and can effectively prevent and treat pathogenic diarrhea caused by one or more pathogens, including porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus, porcine rotavirus, and enterotoxigenic Escherichia coli. They improve the intestinal morphology and absorption function of sick pigs and reduce the morbidity and mortality of piglets.

The invention provides a recombinant LLC-PK1 cell line capable of stably expressing a TGEV-N gene and application of the recombinant LLC-PK1 cell line in promotion of virus rescue, and belongs to the technical field of gene engineering. The invention provides a recombinant LLC-PK1 cell line capable of stably expressing TGEV-N. The recombinant LLC-PK1 cell line capable of stably expressing TGEV-N. The recombinant LLC-PK1 cell line capable of stably expressing TGEV-Nis obtained by cloning a TGEV-N fragment into a lentiviral vector to construct a recombinant lentiviral plasmid and infecting LLC-PK1 cells through lentivirus packaged by virus rescue. The recombinant LLC-PK1 cell capable of stably expressing the TGEV-N is beneficial to rescue of TGEV infectious cloned viruses, so that a tool is provided for researching a virus pathogenic mechanism and a novel genetic engineering vaccine.

The application discloses application of a host PRKCSH gene as a target point in prevention and treatment of various RNA virus infections. Experiments prove that knocking out the PRKCSH gene of a pig can significantly inhibit adhesion and invasion of Japanese B encephalitis virus to a host cell, and can also significantly inhibit replication of a classical swine fever virus, a porcine transmissible gastroenteritis virus, a Senecavirus, a porcine epidemic diarrhea virus and a porcine reproductive and respiratory syndrome virus in the host cell. In addition, knocking out the PRKCSH gene of a human can significantly inhibit replication of the Japanese B encephalitis virus in the host cell. Therefore, specific targeted editing of the PRKCSH gene or interference with protein expression of the PRKCSH gene can inhibit infection of various RNA viruses to host cells.

The invention relates to the technical field of biology, and particularly discloses a pea active peptide and application thereof in inhibiting porcine coronavirus. The toxicity of pea active peptides EHYDSEAILFKK with different concentrations on Vero cells and ST cells is determined through a CCK-8 test, and it is proved that the pea peptide has no toxic effect on the cells; indirect immunofluorescence, virus copy number, immunoblotting and half tissue infection amount are used for determining that the pea active peptide EHYDSEAILFKK has an inhibition effect on porcine epidemic diarrhea virus in Vero cells and porcine transmissible gastroenteritis virus in ST cells; animal experiments show that piglets with 200 [mu] M of pea active peptide can significantly inhibit in-vivo replication of PEDV and TGEV. Therefore, the pea active peptide can obviously inhibit the replication of the porcine epidemic diarrhea virus and the porcine transmissible gastroenteritis virus in vivo and in vitro, and has a broad-spectrum effect of resisting the porcine coronavirus.

The application discloses a kind of pig multiple diarrhea virus detection method and application based on tNGS technology.The method realizes the accurate detection of pig epidemic diarrhea virus, porcine transmissible gastroenteritis virus and porcine delta coronavirus by tNGS technology.The primer set involved is used to amplify the S1 and M genes of PEDV, the N gene of TGEV and the M gene of PDCoV.The application also provides a kit comprising the primer set and a corresponding tNGS detection method.Clinical sample verification shows that the method is completely consistent with the qPCR detection results, has high sensitivity, strong specificity, can simultaneously identify mixed infection and other advantages, and has high detection throughput, controllable cost, is suitable for accurate diagnosis, epidemiological monitoring and prevention and control of diarrhea virus in pig farm, and has wide application prospect.

The invention relates to a swine coronavirus triple subunit nanoparticle vaccine and a preparation method thereof, and belongs to the technical field of veterinary vaccines, the vaccine is obtained by assembling a mixed antigen ST-PPTAg and SC-MI3 according to a proportion, the mixed antigen ST-PPTAg is composed of ST-PEDVCOE, ST-PDCoVRBD and ST-TGEVRBD, and the mixed antigen ST-PPTAg is composed of ST-PEDVCOE, ST-PDCoVRBD and ST-TGEVRBD. The ST-PEDVCOE, the ST-PDCoVRBD and the ST-TGEVRBD are sequentially a porcine epidemic diarrhea virus S protein COE, a porcine delta coronavirus S protein RBD and a porcine transmissible gastroenteritis virus S protein RBD of which the N end is coupled with molecular glue SpyTag003, and the SC-MI3 is a super-stable nanoparticle MI3 of which the N end is coupled with molecular glue SpyCatcher 003. After acting on a body, the porcine coronavirus triple subunit nanoparticle vaccine provided by the invention can stimulate the body to generate a high-titer neutralizing antibody, so that a strong cellular immune effect is achieved, and the lasting period of the antibody can be remarkably prolonged; excellent vaccine candidates are provided for prevention and control of the porcine epidemic diarrhea virus, the porcine delta coronavirus and the porcine transmissible gastroenteritis virus.

The application belongs to the field of biological detection, and particularly relates to sgRNA and RPA primer group, a detection system and application for synchronous detection of four pig-derived viruses. The sgRNA and RPA primer group for synchronous detection of four pig-derived viruses comprises sgRNA and RPA primer group for detecting porcine acute diarrhea syndrome coronavirus, porcine rotavirus, porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. The application further provides a centrifugal microfluidic chip for synchronous detection of four pig-derived viruses, which can be used to synchronously and highly specifically identify multiple pig-derived viruses and accurately distinguish infection types in a single detection process, and the detection result has both laboratory-level sensitivity and accuracy.

This invention provides a mutant S protein of porcine transmissible gastroenteritis virus (TGEV), a subunit vaccine, and its application; the amino acid sequence of the S protein mutant is shown in SEQ ID NO.3. The S protein mutant of TGEV constructed by this invention is significantly superior to the wild-type SWT protein in both humoral and cellular immunity, and its protein expression level also shows a clear advantage, demonstrating excellent prospects for subunit vaccine development and application. Specifically, in terms of immunity, after the S protein mutant is formulated into a vaccine, this invention can enhance post-immunization antibody levels, TGEV virus neutralizing antibody titers, cellular immune responses, and T lymphocyte proliferation.

The invention provides an S protein mutant of a swine transmissible gastroenteritis virus, a subunit vaccine and application. The amino acid sequence of the S protein mutant is as shown in SEQ ID NO. 3. The S protein mutant of the swine transmissible gastroenteritis virus constructed by the invention is obviously superior to an SWT wild type protein in humoral immunity and cellular immunity, and the protein expression quantity also shows an obvious advantage, so that the S protein mutant has a very good subunit vaccine research, development and application prospect; specifically, in the aspect of immunization, after the S protein mutant is prepared into a vaccine, the post-immunization antibody level, the TGEV virus neutralizing antibody titer, the cellular immune response and the T lymphocyte proliferation effect can be improved.